2.59
price down icon1.52%   -0.04
after-market Dopo l'orario di chiusura: 2.59
loading
Precedente Chiudi:
$2.63
Aprire:
$2.62
Volume 24 ore:
100.87K
Relative Volume:
0.48
Capitalizzazione di mercato:
$83.99M
Reddito:
$875.70K
Utile/perdita netta:
$-39.57M
Rapporto P/E:
-1.9295
EPS:
-1.3423
Flusso di cassa netto:
$-33.65M
1 W Prestazione:
-7.17%
1M Prestazione:
+1.97%
6M Prestazione:
-15.64%
1 anno Prestazione:
-50.95%
Intervallo 1D:
Value
$2.56
$2.69
Intervallo di 1 settimana:
Value
$2.56
$2.9599
Portata 52W:
Value
$2.22
$5.74

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name
Nome
Vistagen Therapeutics Inc
Name
Telefono
650-577-3600
Name
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Name
Dipendente
0
Name
Cinguettio
@vistagen
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
VTGN's Discussions on Twitter

Confronta VTGN con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
VTGN
Vistagen Therapeutics Inc
2.59 83.99M 875.70K -39.57M -33.65M -1.3423
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-07 Aggiornamento Jefferies Hold → Buy
2023-08-07 Aggiornamento Maxim Group Hold → Buy
2022-07-22 Downgrade Jefferies Buy → Hold
2022-07-22 Downgrade Robert W. Baird Outperform → Neutral
2022-07-22 Downgrade William Blair Outperform → Mkt Perform
2021-05-20 Iniziato Robert W. Baird Outperform
2021-02-18 Iniziato Jefferies Buy
2021-01-04 Aggiornamento William Blair Mkt Perform → Outperform
2018-06-27 Iniziato Maxim Group Buy
2018-02-08 Reiterato Chardan Capital Markets Buy
2017-03-28 Iniziato Maxim Group Buy
Mostra tutto

Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie

pulisher
Mar 24, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat

Mar 24, 2025
pulisher
Mar 21, 2025

Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR

Mar 21, 2025
pulisher
Mar 21, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World

Mar 21, 2025
pulisher
Mar 19, 2025

Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise

Mar 19, 2025
pulisher
Mar 19, 2025

Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan

Mar 19, 2025
pulisher
Mar 14, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat

Mar 14, 2025
pulisher
Mar 12, 2025

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com

Mar 12, 2025
pulisher
Mar 08, 2025

VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 04, 2025

Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire

Mar 04, 2025
pulisher
Mar 04, 2025

Can Vistagen's Innovative Pherine Technology Disrupt the Neuroscience Market? CEO Presents at Major Forum - StockTitan

Mar 04, 2025
pulisher
Mar 02, 2025

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN

Mar 02, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com

Feb 27, 2025
pulisher
Feb 27, 2025

VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 25, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat

Feb 25, 2025
pulisher
Feb 20, 2025

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan

Feb 20, 2025
pulisher
Feb 19, 2025

VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire

Feb 19, 2025
pulisher
Feb 18, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Announces Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat

Feb 18, 2025
pulisher
Feb 15, 2025

Vistagen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50 Day Moving AverageHere's What Happened - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates - MSN

Feb 15, 2025
pulisher
Feb 15, 2025

Vistagen Therapeutics Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Feb 15, 2025
pulisher
Feb 14, 2025

VistaGen’s Earnings Call: Progress and Challenges - TipRanks

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication (NASDAQ:VTGN) - Seeking Alpha

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance

Feb 14, 2025
pulisher
Feb 14, 2025

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlight - GuruFocus.com

Feb 14, 2025
pulisher
Feb 14, 2025

VistaGen Reports Q3 2025 Financial Results and Updates - TipRanks

Feb 14, 2025
pulisher
Feb 13, 2025

Vistagen Reports Q3 Earnings and Pipeline Progress - TipRanks

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen advances Phase 3 SAD trials with 2025 data readout target - MSN

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - sharewise

Feb 13, 2025
pulisher
Feb 13, 2025

Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss - Investing.com

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView

Feb 13, 2025
pulisher
Feb 13, 2025

VistaGen Therapeutics Inc Q3 Loss Increases, But Beats Estimates - Nasdaq

Feb 13, 2025
pulisher
Feb 13, 2025

Vistagen Earnings Reveal $88.6M War Chest, Phase 2A Success Fuels Pipeline Momentum - StockTitan

Feb 13, 2025
pulisher
Feb 12, 2025

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Feb 12, 2025
pulisher
Feb 12, 2025

Earnings To Watch: Vistagen Therapeutics Inc (VTGN) Reports Q3 2025 Result - Yahoo Finance

Feb 12, 2025
pulisher
Feb 07, 2025

Vistagen Therapeutics (VTGN) Projected to Post Earnings on Tuesday - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025 - Marketscreener.com

Feb 06, 2025
pulisher
Feb 06, 2025

USPTO grants patent to Vistagen’s neuropathic pain treatment - Yahoo Finance

Feb 06, 2025
pulisher
Feb 06, 2025

Q3 Earnings Preview: Vistagen to Reveal Latest Progress on Breakthrough Pherine Treatments - StockTitan

Feb 06, 2025
pulisher
Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain - sharewise

Feb 05, 2025
pulisher
Feb 05, 2025

Generalized Anxiety Disorder Pipeline 2024: Mechanism - openPR

Feb 05, 2025
pulisher
Feb 05, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain -February 05, 2025 at 08:38 am EST - Marketscreener.com

Feb 05, 2025
pulisher
Feb 05, 2025

Vistagen secures patent for non-opioid pain treatment By Investing.com - Investing.com UK

Feb 05, 2025
pulisher
Feb 05, 2025

Breakthrough Pain Treatment Patent: Vistagen's Non-Opioid AV-101 Shows Promise Against Gabapentin - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Expands By 46.2% - MarketBeat

Feb 04, 2025

Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Capitalizzazione:     |  Volume (24 ore):